Trial Profile
A trial investigating GBT-440 in sickle cell disease (SCD) patients with HbSC and HbSbeta+ thalassemia genotypes
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2016
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 05 Apr 2016 New trial record
- 29 Mar 2016 According to a Global Blood Therapeutics media release, this trial is expected to start in 2016.